These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21180586)

  • 1. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers.
    Pang SH; Graham DY
    Therap Adv Gastroenterol; 2010 Jan; 3(1):11-22. PubMed ID: 21180586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous proton pump inhibitor therapy: a rationale for use.
    Armstrong D
    Rev Gastroenterol Disord; 2005; 5 Suppl 2():S18-30. PubMed ID: 16369224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal.
    Savarino V; Dulbecco P; de Bortoli N; Ottonello A; Savarino E
    Eur J Intern Med; 2017 Jan; 37():19-24. PubMed ID: 27784575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical use of proton pump inhibitors in gastrointestinal diseases].
    Rew JS
    Korean J Gastroenterol; 2006 Mar; 47(3):181-90. PubMed ID: 16554671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding.
    van Rensburg CJ; Cheer S
    Clin Med Insights Gastroenterol; 2012; 5():51-60. PubMed ID: 24833934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers.
    Laine L; Shah A; Bemanian S
    Gastroenterology; 2008 Jun; 134(7):1836-41. PubMed ID: 18423628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.
    Cheng HC; Sheu BS
    World J Gastrointest Endosc; 2011 Mar; 3(3):49-56. PubMed ID: 21455342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
    Welage LS; Berardi RR
    J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. History of acid suppression: focus on the hospital setting.
    Garnett WR
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):56S-60S. PubMed ID: 14587958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use and Misuse of Proton Pump Inhibitors: An Opportunity for Deprescribing.
    Dharmarajan TS
    J Am Med Dir Assoc; 2021 Jan; 22(1):15-22. PubMed ID: 33321078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis.
    Tringali A; Manta R; Sica M; Bassotti G; Marmo R; Mutignani M
    Br J Clin Pharmacol; 2017 Aug; 83(8):1619-1635. PubMed ID: 28181291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of an intervention in an academic Internal Medicine Clinic to continue, step-down, or discontinue proton pump inhibitor therapy related to a tennessee medicaid formulary change.
    Ramser KL; Sprabery LR; Hamann GL; George CM; Will A
    J Manag Care Pharm; 2009 May; 15(4):344-50. PubMed ID: 19422274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.
    Richardson P; Hawkey CJ; Stack WA
    Drugs; 1998 Sep; 56(3):307-35. PubMed ID: 9777309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
    Lee L; Ramos-Alvarez I; Ito T; Jensen RT
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic properties of proton pump inhibitors.
    Welage LS
    Pharmacotherapy; 2003 Oct; 23(10 Pt 2):74S-80S. PubMed ID: 14587961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
    Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.
    McKeage K; Blick SK; Croxtall JD; Lyseng-Williamson KA; Keating GM
    Drugs; 2008; 68(11):1571-607. PubMed ID: 18627213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.